Edwards Lifesciences divests hemofiltration product business to Baxter International

Editorial Checklist Reviewed

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the sale of certain assets related to its hemofiltration product line to Baxter International Inc. (NYSE: BAX), consistent with the previously announced terms of the agreement.

"The completion of this transaction allows us to better focus resources on our strategic initiatives while benefitting Edwards' hemofiltration employees, products and customers," said Carlyn D. Solomon, Edwards' corporate vice president, Critical Care and Vascular.

Source:

Edwards Lifesciences

Posted in:

Comments (0)

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer